Skip to main content
Ovarian Cancer
Assessing Comprehensive Care Deficits in US Ovarian Cancer Programs to Inform Quality Improvement Initiatives
Read More
Ovarian Cancer
2021 in Review
Read More
Ovarian Cancer
Cost-Effectiveness Analysis of Olaparib and Niraparib as Maintenance Therapy for Women with Recurrent Platinum-Sensitive Ovarian Cancer
Read More
Ovarian Cancer
Phase 2 Placebo-Controlled Study to Assess the Efficacy/Safety of Farletuzumab plus Chemotherapy in Women with Low CA-125 Platinum-Sensitive Ovarian Cancer
Read More
Ovarian Cancer
Phase 2 APPROVE Trial of Apatinib plus Pegylated Liposomal Doxorubicin (PLD) versus PLD for Platinum-Resistant Recurrent Ovarian Cancer
Read More
Ovarian Cancer
Long-Term Safety and Secondary Efficacy End Points in the ENGOT-OV16/NOVA Phase 3 Trial of Niraparib in Recurrent Ovarian Cancer
Read More
Ovarian Cancer
Phase 1 Trial of Ribociclib (LEE-011) with Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer
Read More
Ovarian Cancer
ARIEL4 Results of Rucaparib versus Chemotherapy in Patients with Advanced, Relapsed Ovarian Cancer and a Deleterious BRCA Mutation
Read More
Ovarian Cancer
Progression-Free Survival Benefit from Maintenance Olaparib in Patients with Platinum-Sensitive Relapsed Ovarian Cancer by BRCA and Other Homologous Recombination Repair Gene Mutation Status (ORZORA Trial)
Read More
Ovarian Cancer
Olaparib Treatment in Patients with Platinum-Sensitive Relapsed Ovarian Cancer by BRCA Mutation and Homologous Recombination Deficiency Status: Secondary Safety Results from the Phase 2 LIGHT Study
Read More
Page 70 of 199
Results 691 - 700 of 1986